InMed Pharmaceuticals (INM) Cash & Current Investments (2020 - 2026)

InMed Pharmaceuticals has reported Cash & Current Investments for 7 years, with the latest figure at $5.2 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 10.57% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 10.57% increase from a year earlier, with the FY2025 full-year figure at $10.8 million, up 63.07% from the prior year.
• Cash & Current Investments was $5.2 million for Q1 2026 at InMed Pharmaceuticals, down from $7.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $11.5 million in Q4 2022, with the low at $3.5 million in Q4 2024.
• Average Cash & Current Investments over 5 years is $7.6 million, with a median of $7.0 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments sank 63.04% in 2024, then surged 98.9% in 2025.
• Over 5 years, Cash & Current Investments stood at $11.5 million in 2022, then dropped by 17.01% to $9.6 million in 2023, then tumbled by 63.04% to $3.5 million in 2024, then soared by 98.9% to $7.0 million in 2025, then fell by 25.57% to $5.2 million in 2026.
• The last three Cash & Current Investments figures came in at $5.2 million (Q1 2026), $7.0 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.